Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. Show more

828 Winter Street, Waltham, MA, 02451, United States

https://xiliotx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

49.27M

52 Wk Range

$6.47 - $16.52

Previous Close

$8.52

Open

$8.63

Volume

22,174

Day Range

$8.40 - $8.63

Enterprise Value

-81.86M

Cash

137.5M

Avg Qtr Burn

-1.998M

Insider Ownership

29.48%

Institutional Own.

35.39%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Vilastobart (XTX101)+ atezolizumab Details Metastatic microsatellite stable colorectal cancer (MSS CRC)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efarindodekin Alfa (XTX301) Details Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CLDN18.2 Masked T Cell Engager (T Cell Engager) Details Gastrointestinal And Lung Cancers	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PSMA/STEAP1 Masked T Cell Engager (T Cell Engager) Details Prostate Cancer	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XTX501 Details Solid tumor/s	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XTX202 (monotherapy) Details Renal cell carcinoma, Melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.